Trulicity(dulaglutide)
Trulicity (dulaglutide) is a protein pharmaceutical. Dulaglutide was first approved as Trulicity on 2014-09-18. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Trulicity
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Dulaglutide
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Trulicity | dulaglutide | Eli Lilly | N-125469 RX | 2014-09-18 | 4 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| trulicity | Biologic Licensing Application | 2023-05-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
87 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 20 | 12 | 28 | 11 | 3 | 72 |
| Healthy volunteers/patients | — | 5 | — | — | 1 | — | 6 | ||
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | 2 | — | 3 |
| Overweight | D050177 | E66.3 | — | — | — | 3 | — | 3 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | 1 | 2 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | 2 | — | 2 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | 1 | 1 | 2 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 1 | — | 1 |
| Adiposity | D050154 | — | — | — | 1 | — | 1 | ||
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | N18 | — | 1 | 1 | — | — | 2 | |
| Glucose metabolism disorders | D044882 | — | — | 1 | — | — | 1 | ||
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | 1 | — | — | 1 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | 1 | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | — | — | — | 2 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | — | 1 |
| Exocrine pancreatic insufficiency | D010188 | K86.81 | — | 1 | — | — | — | 1 | |
| Body weight changes | D001836 | — | 1 | — | — | — | 1 | ||
| Smoking cessation | D016540 | EFO_0004319 | — | 1 | — | — | — | 1 | |
| Craving | D066249 | — | 1 | — | — | — | 1 | ||
| Water-electrolyte imbalance | D014883 | — | 1 | — | — | — | 1 | ||
| Thirst | D013894 | — | 1 | — | — | — | 1 | ||
| Psychogenic polydipsia | D059607 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pediatric obesity | D063766 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DULAGLUTIDE |
| INN | dulaglutide |
| Description | Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is a once-weekly injection.
|
| Classification | Protein |
| Drug class | peptides: glucagon-like peptide (GLP) analogs |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 923950-08-7 |
| RxCUI | 1551291 |
| ChEMBL ID | CHEMBL2108027 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09045 |
| UNII ID | WTT295HSY5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Trulicity - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,820 documents
View more details
Safety
Black-box Warning
Black-box warning for: Trulicity
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,493 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more